Clinical Trials Browser

Phase 1/2 × TIC10 compound × Clear all

NCT02392572 2026-03-12

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

17 enrolled 10 charts

Multiple Myeloma

NCT02420795 2022-04-04

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

16 enrolled 14 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell